Actively Recruiting
Phase III Study Comparing BL-M07D1 With Chemotherapy in Women Aged 18 to 75 With HER2-low Recurrent or Metastatic Breast Cancer
Led by Sichuan Baili Pharmaceutical Co., Ltd. · Updated on 2026-01-21
566
Participants Needed
2
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of BL-M07D1 in women with HER2-low breast cancer that cannot be removed by surgery and that has either come back locally or spread to other parts of the body. This phase III, randomized, open-label, multicenter study compares BL-M07D1 with chemotherapy chosen by the patients doctor to better understand treatment options for this condition. Participants receive either BL-M07D1 through intravenous infusion every three weeks or one of several chemotherapy drugs including Capecitabine oral, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel all by infusion. Treatment continues in cycles as long as there is clinical benefit, stopping if the disease progresses or if intolerable side effects occur. During the study, participants will be monitored regularly for up to approximately 24 months. Researchers will assess progression-free survival as the main outcome, along with overall survival, response rates, duration of response, clinical benefit, disease control, treatment-related side effects, and immune responses. Participants will have scans, lab tests, and clinical evaluations as part of safety and effectiveness monitoring throughout their involvement.
CONDITIONS
Brief Title
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
Research Team
S
Sa Xiao, PHD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here